Guvenir Hakan, Dibek Misirlioglu Emine, Capanoglu Murat, Vezir Emine, Toyran Muge, Kocabas Can Naci
Department of Pediatric Allergy and Immunology, Ankara Children's Hematology Oncology Training and Research Hospital, Ankara, Turkey.
Int Arch Allergy Immunol. 2016;169(1):45-50. doi: 10.1159/000443830. Epub 2016 Mar 9.
Parallel to the increasing use of non-β-lactam (NBL) antibiotics, allergic reactions to this drug group seem to increase. Data about NBL antibiotic hypersensitivity in children are limited. The aim of this study is to evaluate characteristic reactions to NBL antibiotics in children.
Patients with suspected NBL allergy were assessed between 2011 and 2015. Characteristics of the reactions and results of skin and drug provocation tests (DPTs) were recorded.
In total, 96 patients aged 75.15 ± 56.77 months (range: 3-208) were assessed. Clarithromycin (63.6%) was the most common cause of reactions reported. After ingestion of NBL antibiotics, maculopapular rash, urticaria/angioedema and anaphylaxis presented in 48.9, 40.7 and 10.4% of the patients, respectively. Tests were performed in 85 patients. Intradermal tests were positive in 3 patients (clarithromycin, ciprofloxacin and cotrimoxazole) and DPT was positive in 1 patient (clarithromycin). Eleven patients could not be tested. Seven patients had severe anaphylaxis, and 4 patients with urticaria/angioedema had to take their medications at the time of the reaction so desensitization was performed. When only patients confirmed by tests were evaluated, NBL allergy was 4.7% (4/85) in our study group. However, when patients who could not be tested, but were regarded as suffering from drug hypersensitivity according to clinical findings, were included, the frequency of NBL allergy was 15.6% (15/96).
Most of the children with suspected NBL do not have true hypersensitivity. The frequency of confirmed hypersensitivity is low, and thus a detailed history should be taken from patients with suspected NBL hypersensitivity and DPTs should be performed in patients without contraindications.
随着非β-内酰胺(NBL)类抗生素使用的增加,对该类药物的过敏反应似乎也在增多。关于儿童NBL抗生素超敏反应的数据有限。本研究旨在评估儿童对NBL抗生素的特征性反应。
对2011年至2015年间疑似NBL过敏的患者进行评估。记录反应特征以及皮肤和药物激发试验(DPT)结果。
共评估了96例年龄为75.15±56.77个月(范围:3 - 208个月)的患者。报告的反应中,克拉霉素(63.6%)是最常见的原因。摄入NBL抗生素后,分别有48.9%、40.7%和10.4%的患者出现斑丘疹、荨麻疹/血管性水肿和过敏反应。对85例患者进行了试验。皮内试验在3例患者中呈阳性(克拉霉素、环丙沙星和复方新诺明),DPT在1例患者中呈阳性(克拉霉素)。11例患者无法进行试验。7例患者发生严重过敏反应,4例荨麻疹/血管性水肿患者在反应发生时必须服药,因此进行了脱敏治疗。当仅评估经试验确诊的患者时,我们研究组中NBL过敏率为4.7%(4/85)。然而,当纳入无法进行试验但根据临床发现被视为药物超敏反应的患者时,NBL过敏频率为15.6%(15/96)。
大多数疑似NBL过敏的儿童并非真正的超敏反应。确诊的超敏反应频率较低,因此对于疑似NBL超敏反应的患者应详细询问病史,对无禁忌证的患者应进行DPT。